PMVP

PMVP is a pre-revenue, clinical-stage precision-oncology company whose entire value rests on one asset: rezatapopt, a small molecule targeting the p53 Y220C mutation. The filing is unambiguous that there is no commercial business yet — 'To date, we have not generated any revenue from any sources' — and management 'expect[s] to continue to incur significant losses for the foreseeable future.' The numbers confirm it: FY2025 net loss of -$77.7M (widening 32% YoY), operating cash burn of -$73.6M, R&D up 19% to $69.9M, and a -74% return on equity. This is not a company you value on fundamentals; it is a binary bet on a single trial and regulatory pathway.

What keeps this from being an outright avoid is the balance sheet and the valuation math. Liabilities are tiny (liabilities/equity just 0.11x), and current assets of $115M against $11.4M current liabilities leave ~$104M of net current assets. Against roughly 53.3M shares at $1.23, the market cap is only ~$66M — i.e., the stock trades below its net current assets. The market is effectively assigning negative value to the pipeline, which is the classic setup for a beaten-down biotech where downside is partly cushioned by cash on the books.